Hologic, Inc.
HOLX
株式のランク
#1327
Hologic, Inc. is a medical technology company focused on designing, producing,... Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
株価
$76.01
最終同期: 2026-04-07
時価総額
$16.97B
変化（1日）
0.00%
変化（1年）
8.82%
国
US
取引 Hologic, Inc. (HOLX)
カテゴリー
Healthcare
Hologic, Inc.（HOLX）の営業利益率
October 2026 時点の営業利益率 TTM: 23.34%
Hologic, Inc. の最新の財務報告と株価によると、現在の営業利益率（TTM）は 23.34% です。2024 年末時点では 24.07% でした。
Hologic, Inc. の営業利益率の履歴（2000 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 23.34% | 33.98% |
| 2025 | 17.42% | -27.63% |
| 2024 | 24.07% | 45.17% |
| 2023 | 16.58% | -50.84% |
| 2022 | 33.73% | -23.41% |
| 2021 | 44.04% | 50.51% |
| 2020 | 29.26% | 633.33% |
| 2019 | 3.99% | -153.99% |
| 2018 | -7.39% | -116.50% |
| 2017 | 44.80% | 131.29% |
| 2016 | 19.37% | 15.16% |
| 2015 | 16.82% | 52.22% |
| 2014 | 11.05% | -130.39% |
| 2013 | -36.36% | -740.14% |
| 2012 | 5.68% | -72.86% |
| 2011 | 20.93% | 403.13% |
| 2010 | 4.16% | -103.38% |
| 2009 | -123.18% | 943.90% |
| 2008 | -11.80% | -158.97% |
| 2007 | 20.01% | 83.92% |
| 2006 | 10.88% | -4.06% |
| 2005 | 11.34% | 106.18% |
| 2004 | 5.50% | 271.62% |
| 2003 | 1.48% | 30.97% |
| 2002 | 1.13% | -110.72% |
| 2001 | -10.54% | -63.88% |
| 2000 | -29.18% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 31.28% | -98.66% |
US
|
|
| 12.36% | -99.47% |
FR
|
|
| 0.00% | - |
JP
|
|
| 9.83% | -99.58% |
US
|
|
| 0.00% | - |
CH
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。